Xenotransplantation of human acute myeloid leukemia (AML) cells into immunodeficient mice has allowed to identify leukemiainitiating cells (LIC). 1 Recent studies of phenotypic and genetic tracking of LIC subclones in leukemia patients underscored the use of xenografts to study AML patient's clonal LIC heterogeneity and/or clonal dominance and thus address issues such as patient relapses. 2 Unfortunately, identification of LIC in all AML patients and in all AML subtypes has not been achieved. Lack of successful engraftment has been attributed to clinical and biological prognostic features, antibody-mediated immune clearance and the rarity of LIC in AML. [3] [4] [5] AML3 leukemia has always featured among the good prognostic AML subtypes, and we and others have reported their lack or weak engraftment in NOD-SCID mice. 1, [5] [6] [7] Improved cell separation/preparation techniques and increased immunodeficiency of mouse models were shown to increase engraftment efficiency of cancer-initiating cells. 8, 9 AML3 is a rare leukemia and has thus not yet been reported in this new improved setting. We therefore reinvestigated the issue of LIC in the AML3 subtype using NOD/shi-SCID IL2Rg À / À (NOG) mice.
First, eight AML3 samples were tested for engraftment. AML3 patients' bone marrow (BM) and/or peripheral blood (PB) mononuclear cells were obtained at diagnosis (Supplementary Table S1 ) and injected, after CD3 depletion, intravenously into 6-to 8-week-old NOG mice preconditioned with either sublethal irradiation (3 Gy) or Busulfan treatment (25 mg/kg per day twice 24 h before) (Figure 1a) .
Out of these eight AML3 samples, two samples (Pat. 1 and Pat. 2) successfully engrafted (Figures 1b and c, Supplementary Figure S1A and Table 1), with hCD45 þ CD33 þ CD19 À levels reaching more than 50% at 12 weeks and 20 weeks, respectively, along with immunophenotypic features (CD34, CD38, CD33, CD44 and CXCR4), cytological and molecular (PML-RARA positivity by real-time quantitative PCR and interphase fluorescence in situ hybridization analysis) features similar to the AML3 patients' leukemic cell characteristics at diagnosis (Table 1, Figure 1c and  Supplementary Figure S1A and Supplementary Table S1 ). Two other samples (Pat. 3 and Pat. 4) were also assessed as positive leukemic engrafters, based on the phenotype criteria, hCD45 10 Unfortunately, despite hCD45 þ cells bearing cytology and immunophenotype characteristics similar to those of the AML3 cells' characteristics at diagnosis, AML3 could not be confirmed in these two xenografts by molecular analysis (PML-RAR detection). Xenografts of Pat. 3 samples died before analysis, and hCD45 þ purified from BM and spleen cells of xenografts of Pat. 4 samples yielded too low numbers for successful molecular assays (Table 1) . Furthermore, engraftment kinetics in these two xenografts were poor (Figure 1b) . In three samples (Pat. 6, 7 and 8), only normal human hematopoietic engraftment (CD45 þ CD19 þ cells 475% and CD45 þ CD33 þ cells 420%) was noted, and one AML3 patient sample (Pat. 5) did not engraft after 16 weeks (Table 1) . Thus, in the NOG setting, at least two AML3 samples were confirmed of having successfully engrafted, and allowed to further pursue the experiments to validate the AML3 leukemic subtype (that is, sensitivity to all-trans-retinoic acid (ATRA)) and the existence of AML3 LIC in these patients' samples. Table S2 , data not shown). When mice were transplanted with hCD45 þ BM cells sorted from ATRA-treated mice, the presence of PB and BM PML-RAR þ hCD45 þ cells and hCD34 þ cells was drastically decreased (Supplementary Figure S1C and  Supplementary Table S2 ). These data indicate that ATRA treatment in this AML3 xenograft targeted the LICs, in line with similar results observed in AML3 transgenic mice. 12 In AML xenografts, agents that trigger AML differentiation in vitro, such as activating anti-CD44 antibodies, was equally reported to induce leukemic cell clearance by in vivo differentiation and to target the LIC. 13 In conclusion, we show for the first time the presence of LICs in the AML3 subtype. The fact that not all AML3 samples engrafted emphasizes, as for other AML subtypes, the heterogeneity of AML3. Analysis of various parameters (Supplementary  Table S1 ), including 'classical' M3 versus M3-variant morphology, WBC count, PML-RAR subtype, FLT3 internal tandem duplication
þ or CD47 þ cells, CD44 or CXCR4 level of expression, did not predict engraftment efficiency or normal versus leukemic engraftment. Other criteria such as sample origin (PB versus BM), cell manipulation, storage, NOG mice gender or conditioning via radiotherapy or busulfan were equally not informative for engraftment efficiency.
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These xenograft models open a new perspective to further unravel differential leukemia-initiating pathways triggered by oncogenic events at diagnosis and relapse and analyze drug sensitivity in AML3. The AML3 leukemia subtype is a distinct AML subtype in many aspects, with all patients having the t(15;17) translocations or one of its variants. Although the oncogenic properties of the resulting fusion transcripts have been extensively studied, little data exist on the origin(s) of AML3 in patients. By sorting different cell fractions, Turhan et al.
14 demonstrated, through reverse-transcriptase PCR analysis of CFU (colony-forming unit) blast colonies from an AML3 patient, that the CD34 þ CD38
À leukemic population was not part of the leukemic clone. Since then, no analysis has confirmed these data in a functional setting. In a transgenic MRP8-PML-RAR bcr1 mouse, Tenen's group revisited the cell of origin of the leukemia-initiating cells. 15 Although their results suggest that the AML3-initiating cell Table 1 and Supplementary Table S1 . Engrafted hCD45 þ CD33 þ CD19 À cells were assessed in the PB. Cell percentages are shown for each evaluated mice per patient sample. Bars represent the mean of % hCD45
Representative leukemic cell characteristics from an AML3 BM sample at diagnosis and in the corresponding AML3 xenograft at week 12 (Pat. 1). Flow cytometry plots comparing leukemic CD45, CD34, CD33 expression (1, 2) and the absence of normal hematopoietic (CD33 þ CD19 þ ) engraftment (3). Cytospin slides stained with May Grunwald Giemsa (4). Complete information in Table 1 [1] [2] [3] To take advantage of these effects immediately after transplantation, depletion of unwanted T and B cells (CD3/CD19 depletion) is currently used to produce grafts containing not only stem cells but also high numbers of NK cells. 4 Moreover, additional NK cell infusions represent an interesting option for further immunotherapy and have been already used to treat or prevent disease relapse. 5, 6 As cytokine stimulation strongly increases NK cell-mediated antileukemic activity, we investigated the use of haploidentical, interleukin (IL)-15-stimulated CD3/CD19-depleted grafts in combination with induction and low-dose maintenance chemotherapy for treatment of post-transplant relapse.
Eight patients received IL-15-stimulated stem-cell boosts on a compassionate level of use after providing informed consent. Granulocyte-colony stimulating factor-mobilized peripheral blood stem cells were depleted of CD3 þ and CD19 þ cells with the ClinicMACS device (Miltenyi Biotec, Bergisch Gladbach, Germany) as published earlier.
4 CD3/19 À cells (comprising stem cells, NK cells and monocytes) were diluted in RPMI medium containing 10% human AB serum, 2 mM L-glutamine and 10 ng/ml IL-15 under GMP (good manufacturing practice) conditions. Cells were incubated overnight for at least 12 h in tissue culture flasks at a concentration of 10 Â 10 6 cells/ml. Afterwards, cells were washed four times in 0.9% NaCl. Production was performed under the approval of the local authorities according to y4b of the German drug law (AMG).
Grafts were analyzed by flow cytometry for CD34 þ progenitors, CD69 þ -activated NK cells and for residual T and B cells and monocytes (BD, Heidelberg, Germany, Table 1 ). NK cell chimerism in patient 3 was analyzed with a HLA-A2 antibody (One Lambda, Los Angeles, CA, USA). Cytolytic activity of NK cells was tested in a 2-h BATDA-release assay (Perkin Elmer, Waltham, MA, USA) against K562 cells. BrdU (Bromodeoxyuridine)-assay was done as described by the manufacturer (Roche, Basel, Switzerland) after stimulation with phytohemagglutinin (PHA), IL-2, (100 international units), muronomab-CD3 (Orthoclone OKT-3, pokeweed mitogen (PWM) and concanavalin A (ConA). Thymidine assay was conducted as described earlier. 7 First, we tested the NK cell activity of CD3/19-depleted cells after cytokine stimulation in vitro. IL-15-stimulated CD3/19 À cells had a significantly higher lytic activity than that of unstimulated cells (61% versus 25%) or IL-2-stimulated cells (61% versus 41%). A combination of IL-2 and IL-15 did not further increase lysis (Figure 1a) . No effect was seen with IL-18, whereas the effect of IL-12 was similar to that of IL-2. On the basis of these findings we established an ex vivo stimulation protocol under GMP conditions. Altogether 11 procedures were done. The stimulation led to upregulation of CD69 on NK cells (mean 96.8%, range 90.1-99.6) and did not affect viability (mean 96.5%, range 89.2-99.5). Recovery of NK cells after stimulation was 88.4% (range 40.4-244.5). Stem cell progenitors seemed not to be hampered by the procedure, as recovery of vital CD34 þ was 86% (Table 1) . Unstimulated products Accepted article preview online 22 June 2012; advance online publication, 20 July 2012
